Biological markers in risk stratification and progression of cardiovascular disease: present and future

Taking into account the increase in the level of cardiovascular diseases in recent decades, the clinician faces the task of attempting to make the fastest possible diagnosis of the pathology at its earliest stages. That is why the aim of our work was to identify the main groups of biological markers, and to separate the role of each of them in the assessment of the risk of development, progression and possible complications of cardiovascular diseases. We have given the main working classification of markers of cardiovascular processes with the allocation of their main types, as well as the basic criteria for the “ideal” biological marker. Finally, an attempt was made to structure biomarkers depending on their molecular mechanisms of pathogenesis in the development of a particular pathology. All these data should help the clinician at the stage of early diagnosis of cardiovascular disease.

1. Kalyuzhin V.V., Teplyakov A.T., Solovtsov M.A., Kalyuzhina E.V., Bespalova I.D., Terentyeva N.N. Remodeling of the left ventricle: one or several scenarios? Byulleten’ sibirskoy meditsiny – Bulletin of Siberian Medicine. 2016; 15 (4): 120–139 (in Russ.). DOI: 10.20538/1682-0363-2016-4-120-139.

2. Kalyuzhin V.V., Teplyakov A.T., Kalyuzhin O.V. Heartfailure. Мoscow: Medicinskoe informacionnoe agentstvo Publ., 2018: 376 (in Russ.).

3. Berezin A.E.. Biological markers of cardiovascular disease. Guide for doctors: In 3 parts. Kiev: Morion Publ., 2014. Part 1: 652 (in Russ.).

4. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001; 69 (3): 89–95. DOI: 10.1067/mcp.2001.113989.

5. Colburn W.A. Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development. J. Clin. Pharmacol. 2000; 40 (12 Pt. 2): 1419–1427.

6. De Gruttola V.G., Clax P., de Mets D.L. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Control Clinical. Trials. 2001; 22 (5): 485–502. DOI:10.1016/S0197-2456(01)00153-2.

7. Manolio T. Novel risk markers and clinical practice. N. Engl. J. Med. 2003; 349 (17): 1587–1589. DOI: 10.1056/nejmp038136.

8. Dowd J.B., Zajacova A. Does self-rated health mean the same thing across socioeconomic groups? Evidence from biomarker data. Ann. Epidemiology. 2010; 20 (10): 743– 749. DOI: 10.1016/j.annepidem.2010.06.007.

9. Kumar M., Sarin S.K. Biomarkers of diseases in medicine. Current Trends in Sciens. Platinum Jubilee Special. 2005; 12: 403–417.

10. Sadvakas A.S. Modern concepts of ideal biomarkers in medicine. Sovremennay amedicina: aktual’niyevoprosya – Modern Medicine: Topical Issues. 2014; 5 (31): 230–231 (in Russ.).

11. Miroshnichenko I.I., Ptitsyna S.N. Biomarkers in the modern medical and biologic practice. Biomedicinskaya himiya – Biomedical Chemistry. 2009; 4 (55): 425–440 (in Russ.)

12. Saprygin D.B. Biomarkers: new clinical opportunities and role in understanding the mechanisms of development of cardiac pathology. IFCC Word Lab. and Euro Med. Lab. 2011; 5 (15–19): 69–70 (in Russ.).

13. Ostrovskii O.V. Laboratory markers of myocardial damage in modern cardiology. Vestnik Volgogradskogo medicinskogo universiteta – Bulletin of Volgograd State Мedical University. 2009; 1 (29): 11–15 (in Russ.).

14. Ahmad T., Fiuzat M., Felker G.M., O’Connor C. Novel biomarkers in chronic heart failure. Nat. Rev. Cardiol. 2012; 9: 347–359.

15. Du W., Piek A., Schouten E.M., van de Kolk C.W.A., Mueller C., Mebazaa A., Voors A.A., de Boer R.A., Sil ljé H.H.W. Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production. Theranostics. 2018; 8 (15): 4155–4169. DOI: 10.7150/thno.26055.

16. Qu W., Si S., Sun L., Zhang F., Zhang S., Mu S., Zhao Y., Liu B., Cao X. Construction of a microRNAassociated feedforward loop network that identifies regulators of cardiac hypertrophy and acute myocardial infarction. Int. J. Mol. Med. 2018; 42 (4): 2 062–2070. DOI: 10.3892/ijmm.2018.3790.

17. Kalyuzhin V.V., Urazova O.I., Kalyuzhina E.V., Sibireva O.F., Tkalich L.M., Zibnitskaya L.I., Terent’yeva N.N. Nonspecific mechanisms of chronic kidney disease progression. Byulleten’ sibirskoy meditsiny – Bulletin of Siberian Medicine. 2015; 14 (4): 87–98 (in Russ.). DOI: 10.20538/1682-0363-2015-4-87-98.

18. Teplyakov A.T., Grakova E.V., Kalyuzhin V.V., Tarasov N.I., Shilov S.N., Berezikova E.N., Kuznetsova A.V., Aptekar V.D., Pushnikova E.J., Andriyanova A.V., Sin’kova M.N., Isakov L.K. New opportunities for acute decompensated heart failure diagnostics and clinical value of growth factors: VEGF, PDGF-AB, FGF basic, tissue inhibitor of metalloproteinase-1, and lipoprotein-associated phospholipase A2. Sibirskiy meditsinskiy zhurnal – Siberian Medical Journal. 2015; 30 (2): 50–60 (in Russ.). DOI: 10.29001/2073-8552-2015-30-2-50-60.

19. Teplyakov A.T., Kuznetsova A.V., Protopopova N.V., Andriyanova A.V., Suslova T.E., Nasanova O.N., Kalyuzhin V.V. Lipoprotein-associated phospholipase A2 in cardiovascular risk stratification after coronary angioplasty in patients with type 2 diabetes: which decision rule threshold to choose? Byulleten’ sibirskoy meditsiny – Bulletin of Siberian Medicine. 2015; 14 (2): 47–54 (in Russ.). DOI: 10.20538/1682-0363-2015-2-47-54.

20. Teplyakov A.T., Akhmedov S.D., Suslova T.Y., Andriyanova А.V., Kuznetsova A.V., Protopopova N.V., Kalyuzhin V.V., Nasanova O.N. Influence of resistin on the course of ischemic heart disease in patients with type 2 diabetes mellitus. Byulleten’ sibirskoy meditsiny – Bulletin of Siberian Medicine. 2015; 14 (5): 73–82 (in Russ.). DOI: 10.20538/1682-0363-2015-5-73-82.

21. Teplyakov A.T., Grakova E.V., Berezikova E.N., Shilov S.N., Kopeva K.V., Kalyuzhin V.V. Early markers of progression of heart failure and apoptosis: their role in predicting the risk of adverse cardiovascular events in patients with prior myocardial infarction. Byulleten’ sibirskoy meditsiny – Bulletin of Siberian Medicine. 2016; 15 (1): 37–46 (in Russ.). DOI: 10.20538/1682-0363-2016-1-37-46.

22. Teplyakov A.T., Pyshnikova E. Yu., Andriyanova A.V., Kalyuzhin V.V., Suslova T.E., Nikonova E.N., Karpov R.S. Myocardial and arterial stiffness – important determinant of NT-ProBNP at development of heart failure in survivors of myocardial infarction. Kardiologija – Cardiology. 2016; 56 (4): 42– 48 (in Russ.). DOI: 10.18565/cardio.2016.4.42-48.

23. Ho J.E., Lyass A., Courchesne P., Chen G., Liu C., Yin X., Hwang S.J., Massaro J.M., Larson M.G., Levy D. Protein biomarkers of cardiovascular disease and mortality in the community. J. Am. Heart Assoc. 2018; 7 (14). pii: e008108. DOI: 10.1161/JAHA.117.008108.

24. Bar-Or D., Lau E., Rao N., Bampos N. Reduction in the cobalt binding capacity of human albumin with myocardial ischemia. Ann. Emerg. Med. 1999; 34: 56. DOI: 10.1016/s0196-0644(99)80299-6.

25. Litus E.A., Zaitsev V.G., Verovskii V.E. Cobalt-binding capacity of blood serum: is it a new promising diagnostic test? Biomedicinskajahimija – Biomedical Сhemistry. 2014; 60 (4): 487–92 (in Russ.). DOI: 10.18097/pbmc20146004487.

26. Bar-Or D., Lau E., Winkler J.V. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J. Emerg. Med. 2000; 19 (4): 311–315. DOI: 10.1016/s0736-4679(00)00255-9.

27. Wu A. In: International workshop on ischemia. Barcelona, Spain, 2002: 18–20.

28. Timin O.A. Lectures on general biochemistry. 2018: 352 (in Russ.).

29. Parkhomenko A.N., Irkin O.I., Lutay J.M. The role of biological markers in emergency cardiology. Medicina neotlognih sostojanii – Medicine of Еmergency. 2011; 7–8 (38–39): 46–54 (in Russ.).

30. Mair J. Glycogen phosphorylase isoenzyme BB to diagnose ischaemic myocardial damage. Clin. Chim. Acta. 1998; 272 (1): 79–86. DOI: 10.1016/s0009-8981(97)00254-4.

31. Vazques V., Varon J. Frommolecularcardiologytoemergencymedicalpractice: theroleofinflammatorymarkers. The American Journal of Emergency Medicine. 2012; 30 (7): 1210–1211. DOI: 10.1016/j.ajem.2011.07.020.

32. Morrow D.A. Cardiovascular biomarkers. Pathophysiology and disease management. New Jersey: Humana Press, 2006: 620. DOI: 10.1007/978-1-59745-051-5_31.

33. O’Donoghue M., de Lemos J.A., Morrow D.A. Prognostic utility of hearttype fatty acid binding protein in patients with acute coronary syndrome. Circulation. 2006; 114 (6): 550–557. DOI: 1.1161/circulationaha.106.641936.

34. Liang Y., Chan C.P., Cheung K.Y. Cardio detected rapid test for the diagnosis of early acute myocardial infarction. J. Immunoas Immunochem. 2011; 32 (4): 342–352. DOI: 10.1080|15321819.2011.573043.

35. TikhomirovaYu.R., Kontorshchikova K.N. Level of free fatty acids and protein connecting fatty acids as predictor of coronary events. Laboratornaja diagnostika. Medicinskij al’manah. 2016; (2): 29–31 (in Russ.). DOI: 10.21145/2499-9954-2016-2-29-31.

36. Kashtanova E.V., Voevoda M.I., Kuimov A.D., Polonskaya Y.V., Lozhkina N.G., Ragino Y.I. Heart-type fatty acid binding protein in acute coronary syndrome. Rossiiskii kardiologicheskii zhurnal – Russian Journal of Cardiology. 2012; (1): 31–34 (in Russ.). DOI:10.15829/1560-4071-2012-1-31-34.

37. Mel’nik A.A. D-dimer as a marker of thrombosis and its application in clinical practice. Medicinckaja gazeta Zdorov’eUkraini 21 veka – Medical Newspaper Health of Ukraine of the 21st centur. 2017; 24 (421): 23–24 (in Russ.).

38. Hankey G.J. Homocysteine and vascular disease. Lancet. 1999; 354 (9176): 407–413. DOI: 10.1016/s0140-6736(98)11058-9.

39. Shevchenko O.P., Olefrienko G.A. Hyperhomocysteinemia and its clinical significance. Laboratorija – Laboratory. 2002; 1: 3–7 (in Russ.).

40. Shmeleva V.M. Hyperhomocysteinemia and thrombosis. Trombos, hemostaz I reologija – Thrombosis, Нemostasis and Rheology. 2000; 4: 26–29 (in Russ.).

41. Habutija M.Sh., Shevchenko O.P. Homocysteine in coronary heart disease and heart transplant. Moskow: Refarm Publ., 2004: 272 (in Russ.)].

42. Skvortsov U.I. Homocysteine as a risk factor for coronary heart disease. Saratovskii nauchno-medicinskii zhurnal – Saratov Journal of Medical Scientific Research. 2011; 7 (3): 619–624 (in Russ.)

43. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nature Medicine. 2002; 8: 1211–1218. DOI: 10.1038/nm1102-1211.

44. Tabet F., Rye K.A. High-density lipoproteins, inflammation and oxidative stress. Clin. Sci. (Lond). 2009; 116 (2): 87–98. DOI: 10.1042/cs20080106.

45. Recommendations of the European society of cardiology and the European society of atherosclerosis for the treatment of dyslipidemia. European Heart Journal. 2011; 32 (14): 1769–1818. DOI: 10.1093/eurheartj/ehr158.

46. Usmanova Z.A., Rozyhodzhaeva G.A., Aripov A.N. Spectrum of macro-micro elements in atherosclerotic plaques of patients with carotid atherosclerosis. Kardiologija – Cardiology. 2017; 1: 62 (in Russ.).

47. Akent’eva N.P., Sanina N.A., Gizattulin A.R. Dinitrosyl-iron complexes (donor n0) inhibitors of myeloperoxidase, a biomarker of atherosclerosis. Kardiologija – Cardiology. 2017; 2: 39–40 (in Russ.).

48. Goliasch G., Wagner O., Exner M., Koppensteiner R., Maurer G., Schillinger M., Minar E., Mlekusch W., Hoke M. The impact of cellular adhesion molecules on mortality in patients with aterosclerosis. Journal of the American College of Cardiology. 2015; 65 (10): 2074. DOI: 10.1016/s0735-1097(15)62074-5.

49. Iskanrova L.R., Mutalova E.G., Smakaeva E.R. Adhesion molecules and cell-cytokine complex in vascular remodeling in arterial hypertension with metabolic risk factors. Rossiiskii kardiologicheskii zhurnal – Russian Journal of Cardiology. 2008; 5 (73): 14–20 (in Russ.).

50. Jennifer L.G., David C.P. CD40L is transferred to antigen-presenting B cells during delivery of T-cell help. European Journal of Immunology. 2016; 47 (1): 41–50. DOI: 10.1002/eji.201646504.

51. Heng J., Zhou T., Liu C., Shapiro J.P., Brauer M.J., Kiefer M.C., Barr P.J, Mountz J.D. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994; 263: 1759–1762. DOI: 10.1126/science.7510905.

52. Dominguez-Rodriguez A., Avanzas P., Abreu-Gonzalez P. What’s up with neopterin in cardiovascular pathophysiology? International Journal of Cardiology. 2013; 168 (3): 2997–2998. DOI: 10.1016/j.ijcard.2013.04.010.

53. Altwegg L.A., Neidhart M., Hersberger M., Muller S., Eberli F.R., Corti R., Roffi M., Sutsch G., Gay S., Eckardstein A., Wischnewsky M.B., Luscher T.F., Maier W. Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. European Heart Journal. 2007; 8: 941–948. DOI: 10.1093/eurheatj/ehm078.